XOMA Royalty Corporation (XOMA)
| Market Cap | 287.27M |
| Revenue (ttm) | 42.91M |
| Net Income (ttm) | -8.63M |
| Shares Out | 11.97M |
| EPS (ttm) | -0.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,946 |
| Open | 23.93 |
| Previous Close | 24.27 |
| Day's Range | 23.51 - 24.23 |
| 52-Week Range | 18.35 - 35.00 |
| Beta | 0.94 |
| Analysts | Strong Buy |
| Price Target | 69.50 (+189.52%) |
| Earnings Date | May 13, 2025 |
About XOMA
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with... [Read more]
Financial Performance
In 2024, XOMA Royalty's revenue was $28.49 million, an increase of 498.72% compared to the previous year's $4.76 million. Losses were -$19.29 million, -58.33% less than in 2023.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for XOMA stock is "Strong Buy." The 12-month stock price forecast is $69.5, which is an increase of 189.52% from the latest price.
News
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
EMERYVILLE, Calif. and LUND, Sweden, May 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, and BioInvent International AB (“BioInvent”) (Nasdaq Stoc...
XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference
EMERYVILLE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Invest...
XOMA Royalty Completes Sale of Kinnate Pipeline Assets
XOMA Royalty sold the remaining Kinnate pipeline assets for a total of up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits ...
BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3
LUND, SWEDEN / ACCESS Newswire / April 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-clas...
XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist
XOMA aggregates future biotech royalties and milestone rights for stable, diversified revenue streams. However, I believe its preferred shares (under tickers XOMAO and XOMAP) offer attractive yields w...
XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference
EMERYVILLE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA”; NASDAQ: XOMA), the biotech royalty aggregator, announced today Chief Investment Officer, Brad Sitko, will be a ...
XOMA Royalty Declares Quarterly Preferred Stock Dividends
EMERYVILLE, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Roy...
XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements
Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in 2024
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences
Capital will fund Castle Creek's D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors...
XOMA Royalty to Present at Investor Conferences in March
EMERYVILLE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the fol...
XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
EMERYVILLE, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the Opp...
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
Zevra's MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty's portfolio
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
XOMA Royalty has acquired 50 percent of Twist's existing royalty and milestone economics for $15 million XOMA Royalty's portfolio now holds over 100 assets ranging from revenue-generating commercial t...
Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...
XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties
XOMA Royalty Corporation offers diversified revenue streams from milestone and royalty rights in various therapeutic areas, providing stable returns with lower clinical trial risks. The company's pref...
I Am Banking On The Silver Tsunami With Big Dividends
There are sectors that experience demand irrespective of economic climate. I like cold hard cash placed in my account. We discuss big dividends from healthcare, yields +8.3%.
XOMA Stock Dips Amidst Biotech Sector Decline
XOMA (XOMA, Financial), a company engaged in biotechnology royalties, saw its stock price plummet by 5.36%, with the latest price reported at $25.91. The trading volume reached 3,638 shares, represent...
Zevra's MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today Zevra Therapeutics has received approval from the U.S. F...
XOMA Royalty to Present at Upcoming Investor Conferences in September
EMERYVILLE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the fo...
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolute
My 2 Top Royalty Income Picks, Yields Up To 9.5%
Royalty interests present a lucrative opportunity for passive income from the popularity and demand for certain goods.
XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares
XOMA Corporation operates as a biotechnology royalty aggregator, acquiring economic rights to milestones and royalties from approved or clinical-stage drugs. XOMA's diverse IP portfolio spans various ...
XOMA Declares Quarterly Preferred Stock Dividends
EMERYVILLE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to ho...
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review Voucher
EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from Viracta Th...
LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License
LOS ANGELES--(BUSINESS WIRE)--LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleas...